Avicanna Posts Positive Adjusted EBITDA in Q3

The Toronto-based cannabinoid company reported $0.22 million in adjusted EBITDA for the third quarter of 2026 as operating expenses fell.

Updated on Nov. 12, 2026 in Corporate Finance

Avicanna Posts Positive Adjusted EBITDA in Q3

Avicanna Inc. reported positive adjusted EBITDA of $0.22 million for the third quarter of 2026, improving $1.01 million from the same period a year earlier. Third-quarter revenue was $5.73 million, down 10% year over year following Veterans Affairs Canada reimbursement changes in April 2026.

Why it matters

The results show the company reducing costs and narrowing losses despite lower revenue from a changed reimbursement environment in Canada. Management said it believes the business is better positioned to scale domestically and pursue international expansion.

Third-quarter gross profit was $2.92 million, a 51% gross margin, and the company completed a $2.0 million non-convertible debenture financing on October 29, 2026. Avicanna's filing does not provide a forecast for revenue or EBITDA in future quarters.

The players

Avicanna Inc.

A Toronto-based cannabinoid pharmaceutical company that develops and sells proprietary products, including through its MyMedi.ca channel.

Veterans Affairs Canada

The federal department that administers benefits and services for veterans and whose reimbursement changes affected Avicanna's third-quarter revenue.

The details

Avicanna reported an operating loss of $0.27 million, an 80% narrowing, and ended September 30, 2026 with a $0.11 million working capital surplus. The company sold 176,694 proprietary finished-product units in Canada during the first nine months of 2026, and sales through its MyMedi.ca channel rose 16% quarter over quarter. Avicanna also launched 10 initial QUIX Rapid Onset SKUs in Canada.

April 2026: Veterans Affairs Canada reimbursement changes took effect.
September 30, 2026: The third quarter ended and working capital was measured.
October 29, 2026: Avicanna completed a $2.0 million non-convertible debenture financing.
November 12, 2026: Third-quarter results were released and an earnings call was held.

Market Landscape

Avicanna's quarter shows a Canadian cannabinoid company adjusting to a reimbursement environment shaped by Veterans Affairs Canada's April 2026 changes. Its gains came from cost reduction and a 2% sequential revenue increase rather than from a return to prior-year sales levels.

Investors tracking Avicanna should note that the company's earnings improvement came from lower operating expenses while revenue declined. The $2.0 million debenture financing adds a debt obligation to weigh against the company's small working capital surplus.

The takeaway

Positive adjusted EBITDA can come from cost control even when revenue falls, so readers should check whether earnings gains are sustainable. Watching how Avicanna's revenue responds to Canadian reimbursement policy will show whether the improvement holds.